Teva Pharmaceutical Industries Ltd (TEVA)
16.29
-0.01
(-0.06%)
USD |
NYSE |
May 17, 16:00
16.31
+0.02
(+0.12%)
Pre-Market: 20:00
Teva Pharmaceutical Industries Cash from Investing (Quarterly): 144.00M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 144.00M |
December 31, 2023 | 301.00M |
September 30, 2023 | 184.00M |
June 30, 2023 | 302.00M |
March 31, 2023 | 181.00M |
December 31, 2022 | 168.00M |
September 30, 2022 | 147.00M |
June 30, 2022 | 180.00M |
March 31, 2022 | 161.00M |
December 31, 2021 | 246.00M |
September 30, 2021 | 288.00M |
June 30, 2021 | 481.00M |
March 31, 2021 | 508.00M |
December 31, 2020 | 141.00M |
September 30, 2020 | 157.00M |
June 30, 2020 | 313.00M |
March 31, 2020 | 252.00M |
December 31, 2019 | 430.00M |
September 30, 2019 | 224.00M |
June 30, 2019 | 429.00M |
March 31, 2019 | 272.00M |
December 31, 2018 | 74.00M |
September 30, 2018 | 347.00M |
June 30, 2018 | 406.00M |
March 31, 2018 | 1.039B |
Date | Value |
---|---|
December 31, 2017 | 1.912B |
September 30, 2017 | 104.00M |
June 30, 2017 | -86.00M |
March 31, 2017 | 1.516B |
December 31, 2016 | 538.00M |
September 30, 2016 | -32.30B |
June 30, 2016 | -225.00M |
March 31, 2016 | -2.417B |
December 31, 2015 | -293.00M |
September 30, 2015 | -136.00M |
June 30, 2015 | -4.917B |
March 31, 2015 | -219.00M |
December 31, 2014 | -347.00M |
September 30, 2014 | -528.00M |
June 30, 2014 | -187.00M |
March 31, 2014 | -388.00M |
December 31, 2013 | -316.00M |
September 30, 2013 | -299.00M |
June 30, 2013 | -266.00M |
March 31, 2013 | -266.00M |
December 31, 2012 | -409.00M |
September 30, 2012 | -249.00M |
June 30, 2012 | -282.00M |
March 31, 2012 | -194.00M |
December 31, 2011 | -5.491B |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
141.00M
Minimum
Dec 2020
508.00M
Maximum
Mar 2021
261.85M
Average
235.00M
Median
Cash from Investing (Quarterly) Benchmarks
Viatris Inc | -154.30M |
Alvotech | -10.46M |
AstraZeneca PLC | -2.413B |
GSK PLC | -188.99M |
Johnson & Johnson | -464.00M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -124.00M |
Cash from Financing (Quarterly) | -151.00M |
Free Cash Flow | 878.00M |
Free Cash Flow Per Share (Quarterly) | -0.2208 |
Free Cash Flow to Equity (Quarterly) | -59.00M |
Free Cash Flow to Firm (Quarterly) | -25.84M |
Free Cash Flow Yield | 4.79% |